Maria Pytlik

Selektywne modulatory receptorów estrogenowych (SERM) jako alternatywa dla hormonalnej terapii zastępczej u kobiet po menopauzie

Selective estrogen receptor modulators (SERMs) as an alternative to hormonal replacement therapy in postmenopausal women. Results of the clinical trials published in the recent years demonstrated that the risk of hormonal replacement therapy (HRT) in the cardiovascular system and the breast overweights the benefits exerted in the skeletal system. Those results focused the attention on the selective estrogen receptor modulators. In the present study, the mechanism of action, indications and side effects of SERMs of different generations are described. The experimental and clinical data indicate that raloxifene, a representative of II generation SERMs, can be an alternative to the HRT in the prevention and treatment of osteoporosis.